Novel prognostic index based on hemoglobin level and platelet count for diffuse large B-cell lymphoma, not otherwise specified in the R-CHOP era

References

• Gascoyne RD, Campo E, Jaffe ES, Chan WC, Chan JKC, Rosenwald A, Stein H, Swerdlow SH. Diffuse large B-cell lymphoma, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2017;291–297.
   Google Scholar
• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The non-Hodgkin’s lymphoma classification project. Blood 1997;89:3909–3918.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005;23:4117–4126. doi:10.1200/JCO.2005.09.131.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511. doi:10.1038/35000501.
   PubMed Web of Science ®Google Scholar
• Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an international DLBCL rituximab-CHOP consortium program study. Blood 2012;120:3986–3996. doi:10.1182/blood-2012-05-433334.
   PubMed Web of Science ®Google Scholar
• Nyman H, Adde M, Karjalainen-Lindsberg ML, Taskinen M, Berglund M, Amini RM, Blomqvist C, Enblad G, Leppä S. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007;109:4930–4935. doi:10.1182/blood-2006-02-004234.
   PubMed Web of Science ®Google Scholar
• Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Banham AH, Leppä S. Prognostic impact of activated B-cell focused classification in diffuse large Bcell lymphoma patients treated with R-CHOP. Mod Pathol 2009;22:1094–1101. doi:10.1038/modpathol.2009.22.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275–282. doi:10.1182/blood-2003-05-1545.
   PubMed Web of Science ®Google Scholar
• Nakayama S, Yokote T, Akioka T, Hiraoka N, Nishiwaki U, Miyoshi T, Iwaki K, Takayama A, Masuda Y, Hatooka J, et al. Infiltration of effector regulatory T cells predicts poor prognosis of diffuse large B-cell lymphoma, not otherwise specified. Blood Adv 2017;1:486–493. doi:10.1182/bloodadvances.2016000885.
   PubMed Web of Science ®Google Scholar
• Mikhaeel NG. Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now? Leuk Lymphoma 2009;50:1931–1936. doi:10.3109/10428190903275610.
   PubMed Web of Science ®Google Scholar
• Cox MC, Nofroni I, Laverde G, Ferrari A, Amodeo R, Tatarelli C, Saltarelli F, Veggia B, Aloe-Spiriti MA, Ruco L, et al. Absolute lymphocyte count is a prognostic factor for diffuse large B-cell lymphoma. Br J Haematol 2008;141:265–268. doi:10.1111/j.1365-2141.2008.07028.x.
   PubMed Web of Science ®Google Scholar
• Legouffe E, Rodriguez C, Picot MC, Richard B, Klein B, Rossi JF, Commes T. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin’s lymphoma. Leuk Lymphoma 1998;31:351–357. doi:10.3109/10428199809059228.
   PubMed Web of Science ®Google Scholar
• Bairey O, Shacham-Abulafia A, Shpilberg O, Gurion R. Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor. Hematol Oncol 2016;34:184–192. doi:10.1002/hon.2233.
   PubMed Web of Science ®Google Scholar
• Tadmor T, Bari A, Sacchi S, Marcheselli L, Liardo EV, Avivi I, Benyamini N, Attias D, Pozzi S, Cox MC, et al. Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era. Hematologica 2014;99:125–130. doi:10.3324/haematol.2013.088161.
   PubMed Web of Science ®Google Scholar
• Aoki K, Tabata S, Yonetani N, Matsushita A, Ishikawa T. The prognostic impact of absolute lymphocyte and monocyte counts at diagnosis of diffuse large B-cell lymphoma in the rituximab era. Acta Haematol 2013;130:242–246. doi:10.1159/000350484.
   PubMed Web of Science ®Google Scholar
• Ho CL, Lu CS, Chen JH, Chen YG, Huang TC, Wu YY. Neutrophil/lymphocyte ratio, lymphocyte/monocyte ratio, and absolute lymphocyte count/absolute monocyte count prognostic score in diffuse large b-cell lymphoma: useful prognostic tools in the rituximab era. Medicine (Baltimore) 2015;94:e993. doi:10.1097/MD.0000000000000874.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Ristow K, Habermann T, Inwards DJ, Micallef IN, Markovic SN. Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio. Am J Hematol 2010;85:896–899. doi:10.1002/ajh.21849.
   PubMed Web of Science ®Google Scholar
• Hao X, Wei Y, Wei X, Zhou L, Wei Q, Zhang Y, Huang W, Feng R. Glasgow prognostic score is superior to other inflammation-based scores in predicting survival of diffuse large B-cell lymphoma. Oncotarget 2017;8:76740–76748. doi:10.18632/oncotarget.20832.
   PubMedGoogle Scholar
• Li X, Zhang Y, Zhao W, Liu Z, Shen Y, Li J, Shen Z. The Glasgow prognostic score as a significant predictor of diffuse large B cell lymphoma treated with R-CHOP in China. Ann Hematol 2015;94:57–63. doi:10.1007/s00277-014-2167-0.
   PubMed Web of Science ®Google Scholar
• Ochi Y, Kazuma Y, Hiramoto N, Ono Y, Yoshioka S, Yonetani N, Matsushita A, Imai Y, Hashimoto H, Ishikawa T. Utility of a simple prognostic stratification based on platelet counts and serum albumin levels in elderly patients with diffuse large B cell lymphoma. Ann Hematol 2017;96:1–8. doi:10.1007/s00277-016-2819-3.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346:235–242. doi:10.1056/NEJMoa011795.
   PubMed Web of Science ®Google Scholar
• Mori M, Kitamura K, Masuda M, Hotta T, Miyazaki T, Miura AB, Mizoguchi H, Shibata A, Saito H, Matsuda T, et al. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin’s lymphoma. Int J Hematol 2005;81:246–254. doi:10.1532/IJH97.03147.
   PubMed Web of Science ®Google Scholar
• Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258–1265. doi:10.1182/blood-2003-12-4434.
   PubMed Web of Science ®Google Scholar
• Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Pileri S, Pulsoni A, Soubeyran P, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:4555–4562. doi:10.1200/JCO.2008.21.3991.
   PubMed Web of Science ®Google Scholar
• Carmel R. Anemia and aging: an overview of clinical, diagnostic and biological issues. Blood Rev 2001;15:9–18. doi:10.1054/blre.2001.0146.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood 2015;125:22–32. doi:10.1182/blood-2014-05-577189.
   PubMed Web of Science ®Google Scholar
• Moullet I, Salles G, Ketterer N, Dumontet C, Bouafia F, Neidhart-Berard EM, Thieblemont C, Felman P, Coiffier B. Frequency and significance of anemia in non-Hodgkin’s lymphoma patients. Ann Oncol 1998;9:1109–1115.
   PubMed Web of Science ®Google Scholar
• Morrow TJ, Volpe S, Gupta S, Tannous RE, Fridman M. Anemia of cancer in intermediate-grade non-Hodgkin’s lymphoma. South Med J 2002;95:889–896.
   PubMed Web of Science ®Google Scholar
• Hong J, Woo HS, Kim H, Ahn HK, Sym SJ, Park J, Ahn JY, Cho EK, Shin DB, Lee JH. Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy. Cancer Sci 2014;105:1569–1575. doi:10.1111/cas.12544.
   PubMed Web of Science ®Google Scholar
• Chen LP, Lin SJ, Yu MS. Prognostic value of platelet count in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk 2012;12:32–37. doi:10.1016/j.clml.2011.09.215.
   PubMed Web of Science ®Google Scholar
• Means RT. Hepcidin and cytokines in anaemia. Hematology 2004;9:357–362. doi:10.1080/10245330400018540.
   PubMedGoogle Scholar
• Nemeth E, Ganz T. Hepcidin and iron-loading anemias. Haematologica 2006;91:727–732.
   PubMed Web of Science ®Google Scholar
• Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271–1276. doi:10.1172/JCI20945.
   PubMed Web of Science ®Google Scholar
• Maggio M, Guralnik JM, Longo DL, Ferrucci L. Interleukin-6 in aging and chronic disease: a magnificent pathway. J Gerontol A Biol Sci Med Sci 2006;61:575–584. doi:10.1093/gerona/61.6.575.
   PubMed Web of Science ®Google Scholar
• Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW. Hepcidin in human iron disorders: diagnostic implications. Clin Chem 2011;57:1650–1669. doi:10.1373/clinchem.2009.140053.
   PubMed Web of Science ®Google Scholar
• Sharma S, Nemeth E, Chen YH, Goodnough J, Huston A, Roodman GD, Ganz T, Lichtenstein A. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res 2008;14:3262–3267. doi:10.1158/1078-0432.CCR-07-4153.
   PubMed Web of Science ®Google Scholar
• Hohaus S, Massini G, Giachelia M, Vannata B, Bozzoli V, Cuccaro A, D’Alo’ F, Larocca LM, Raymakers RA, Swinkels DW, et al. Anemia in Hodgkin’s lymphoma: the role of interleukin-6 and hepcidin. J Clin Oncol 2010;28:2538–2543. doi:10.1200/JCO.2009.27.6873.
   PubMed Web of Science ®Google Scholar
• Cheng PP, Sun ZZ, Jiang F, Tang YT, Jiao XY. Hepcidin expression in patients with acute leukemia. Eur J Clin Invest 2012;42:517–525. doi:10.1111/j.1365-2362.2011.02608.x.
   PubMed Web of Science ®Google Scholar
• Ciccarelli BT, Patterson CJ, Hunter ZR, Hanzis C, Ioakimidis L, Manning R, Yang G, Xu L, Zhou Y, Sun J, et al. Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011;11:160–163. doi:10.3816/CLML.2011.n.038.
   PubMed Web of Science ®Google Scholar
• Tisi MC, Bozzoli V, Giachelia M, Massini G, Ricerca BM, Maiolo E, D’Alo’ F, Larocca LM, Piciocchi A, Tjalsma H, et al. Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin. Leuk Lymphoma 2014;55:270–275. doi:10.3109/10428194.2013.802314.
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Tasaki T, Tai K, Ikegaya S, Takagi K, Negoro E, Kishi S, Yoshida A, Iwasaki H, Ueda T. Prognostic effect of peripheral blood cell counts in advanced diffuse large B-cell lymphoma treated with R-CHOP-like chemotherapy: a single institution analysis. Oncol Letter 2015;9:851–856. doi:10.3892/ol.2014.2716.
   PubMed Web of Science ®Google Scholar
• Bloomfield CD, McKenna RW, Brunning RD. Significance of haematological parameters in the non-Hodgkin’s malignant lymphomas. Br J Hematol 1976;32:41–46. doi:10.1111/j.1365-2141.1976.tb01873.x.
   PubMed Web of Science ®Google Scholar
• Conlan MG, Armitage JO, Bast M, Weisenburger DD. Clinical significance of hematologic parameters in non-Hodgkin’s lymphoma at diagnosis. Cancer 1991;67:1389–1395.
   PubMed Web of Science ®Google Scholar
• Hauswirth AW, Skrabs C, Schützinger C, Raderer M, Chott A, Valent P, Lechner K, Jäger U. Autoimmune thrombocytopenia in non-Hodgkin’s lymphomas. Haematologica 2008;93:447–450. doi:10.3324/haematol.11934.
   PubMed Web of Science ®Google Scholar
• Lehman HA, Lehman LO, Rustagi PK, Rustgi RN, Plunkett RW, Farolino DL, Conway J, Logue GL. Complement-mediated autoimmune thrombocytopenia. Monoclonal IgM antiplatelet antibody associated with lymphoreticular malignant disease. N Engl J Med 1987;316:194–198. doi:10.1056/NEJM198701223160406.
   PubMed Web of Science ®Google Scholar